| 5.03 0.19 (3.93%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.19 | 1-year : | 7.23 |
| Resists | First : | 5.3 | Second : | 6.19 |
| Pivot price | 4.37 |
|||
| Supports | First : | 3.65 |
Second : | 2.64 |
| MAs | MA(5) : | 4.9 |
MA(20) : | 4.19 |
| MA(100) : | 2.6 |
MA(250) : | 1.73 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 83 |
D(3) : | 81.6 |
| RSI | RSI(14): 72.9 |
|||
| 52-week | High : | 5.3 | Low : | 0.64 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IRD ] has closed below upper band by 20.9%. Bollinger Bands are 171.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 34 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.21 - 5.24 | 5.24 - 5.26 |
| Low: | 4.78 - 4.81 | 4.81 - 4.83 |
| Close: | 4.98 - 5.03 | 5.03 - 5.07 |
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Sat, 14 Mar 2026
Opus Genetics, Inc. (IRD) reports Q4 loss, tops revenue estimates - MSN
Thu, 12 Mar 2026
Opus Genetics (IRD) Target Price Raised by Wedbush Analyst | IRD Stock News - GuruFocus
Thu, 12 Mar 2026
Opus Genetics (IRD) Gets a Buy from H.C. Wainwright - The Globe and Mail
Thu, 12 Mar 2026
BTIG Raises its Price Target on Opus Genetics, Inc. (IRD) to $12 from $7 and Maintains a Buy Rating - Yahoo Finance
Wed, 11 Mar 2026
Craig-Hallum Maintains Buy on Opus Genetics (IRD) March 2026 - Meyka
Wed, 11 Mar 2026
Opus Genetics (IRD) Trailing US$49.6m Loss Reinforces Bearish Profitability Narrative - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 15.3 (%) |
| Held by Institutions | 40.3 (%) |
| Shares Short | 942 (K) |
| Shares Short P.Month | 958 (K) |
| EPS | -1.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.09 |
| Profit Margin | 0 % |
| Operating Margin | -270 % |
| Return on Assets (ttm) | -60.8 % |
| Return on Equity (ttm) | -338.8 % |
| Qtrly Rev. Growth | -20.4 % |
| Gross Profit (p.s.) | -0.19 |
| Sales Per Share | 0.21 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -2.71 |
| PEG Ratio | 0 |
| Price to Book value | 55.88 |
| Price to Sales | 23.7 |
| Price to Cash Flow | -10.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|